BMY Stock Analysis: Buy, Sell, or Hold?
BMY - Bristol-Myers Squibb Co.
$59.55
1.01 (1.73%)
▲
5d:
+4.47%
30d:
-4.52%
90d:
+8.99%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Apr 30, 2026
30d
Smart Money Accumulation
BMY is down 4.5% this week, but smart money is accumulating calls. Top strike: $57.5 2026-06-18 with 10,738 OI. Call ratio: 63% View Scanner →
Strength: 3.5/10
Get Alerted When BMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BMY shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: BMY shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.80
Based on 0.9% avg growth
INTRINSIC VALUE TODAY
$37.13
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMY is currently trading at $59.55, which is considered oversold relative to its 30-day fair value range of $58.58 to $61.42. The stock's valuation (Forward PE: 9.5) is in line with its historical norms (9.3). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BMY is in a strong uptrend. The price is approaching resistance at $60.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMY is in a strong uptrend. The price is approaching resistance at $60.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$58.58 -
$61.42
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($62.72)
- NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$58.58 -
$61.42
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$56.45
Resistance Level
$60.81
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.53
Wall Street Target
$62.72
(+7.1%)
Revenue Growth (YoY)
1.3%
Earnings Growth (YoY)
1392.1%
Profit Margin
14.6%
Valuation Premium vs History
+0.7% premium
PE vs Historical
9.5 vs 9.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$58.95
(+1%)
2-Year Target
$59.36
(+1%)
3-Year Target
$59.78
(+2%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$58.31
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: -2.1%)
$129.06
(+121%)
Base:
(SPY PE: 9.5, Growth: -2.1%)
$54.93
(-6%)
Bear:
(PE: 8.1, Growth: -2.1%)
$46.69
(-20%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 16.61 | Current EPS (TTM): $3.46
Bull Case
$112.21
(+97%)
Analyst growth 77.5%, PE expands to 18.3
Base Case
$102.01
(+79%)
Market implied 77.5%, PE stable at 16.6
Bear Case
$39.09
(-31%)
Severe decline -20.0%, PE contracts to 14.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 30, 2026 10:19 AM ET
Data refreshes hourly during market hours. Next update: 11:19 AM
Data refreshes hourly during market hours. Next update: 11:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMY showing a specific setup today?
Insider Activity (6 Months)
5
Buys
4
Sells
+
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-02-05
Ro Khanna
SELL
2026-01-29
Ro Khanna
BUY
2026-01-23
Featured in Portfolios
BMY is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 51 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 57 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 62 BUY |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$128 | 68 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 58 HOLD |
Advanced BMY Option Strategies
Professional options setups generated by AI based on today's BMY price and gamma walls.
